GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Chongqing Lummy Pharmaceutical (SZSE:300006) » Definitions » Additional Paid-In Capital

Chongqing Lummy Pharmaceutical (SZSE:300006) Additional Paid-In Capital : ¥0.0 Mil(As of Mar. 2024)


View and export this data going back to 2009. Start your Free Trial

What is Chongqing Lummy Pharmaceutical Additional Paid-In Capital?


Chongqing Lummy Pharmaceutical's quarterly additional paid-in capital increased from Sep. 2023 (¥0.0 Mil) to Dec. 2023 (¥1,483.4 Mil) but then stayed the same from Dec. 2023 (¥1,483.4 Mil) to Mar. 2024 (¥0.0 Mil).

Chongqing Lummy Pharmaceutical's annual additional paid-in capital increased from Dec. 2021 (¥1,459.0 Mil) to Dec. 2022 (¥1,474.7 Mil) and increased from Dec. 2022 (¥1,474.7 Mil) to Dec. 2023 (¥1,483.4 Mil).


Chongqing Lummy Pharmaceutical Additional Paid-In Capital Historical Data

The historical data trend for Chongqing Lummy Pharmaceutical's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Chongqing Lummy Pharmaceutical Additional Paid-In Capital Chart

Chongqing Lummy Pharmaceutical Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 645.25 630.41 1,458.96 1,474.75 1,483.42

Chongqing Lummy Pharmaceutical Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 1,474.75 - 1,483.42 -

Chongqing Lummy Pharmaceutical Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

Chongqing Lummy Pharmaceutical Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of Chongqing Lummy Pharmaceutical's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


Chongqing Lummy Pharmaceutical (SZSE:300006) Business Description

Traded in Other Exchanges
N/A
Address
99 Yuma Road, Nan'an District, chongqing, CHN, 401123
Chongqing Lummy Pharmaceutical is a wholly-owned subsidiary of Lai America Pharmaceutical Co., Ltd. and is a professional pharmaceutical sales company in China.
Executives
Yuan Yuan Supervisors
Qiu Yu Directors, executives
Leng Xue Feng Secretary, Director
Zhang Xiao Xue Supervisors
Wang Ying Director
Zhou Xue Mei Supervisors
Zhao Bin Executives
Tang Xiao Hai Executives
Fu Rong Executives
Li Xian Feng Supervisors
Qiu Wei Director

Chongqing Lummy Pharmaceutical (SZSE:300006) Headlines

No Headlines